Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
What is the Anticipated CAGR of the Glaucoma Market, and What Factors Will Drive It?
In the past few years, the glaucoma market has seen robust growth. It is projected to increase from $7.76 billion in 2024 to $8.22 billion in 2025, following a compound annual growth rate (CAGR) of 5.9%. Factors contributing to the growth during the historical period include heightened awareness about eye health, increased healthcare expenditure, a rising trend of utilizing telemedicine for eye care, growth in healthcare infrastructure, and government initiatives in healthcare.
There is anticipated substantial growth in the glaucoma market in the coming years. It is expected to expand to $10.20 billion by 2029 with a compound annual growth rate (CAGR) of 5.5%. This anticipated growth during the projected period can be linked to an aging population, increased incidents of glaucoma, growing need for less invasive surgical procedures, a rise in diabetes cases, and an increase in hypertension prevalence. Key trends during this forecast period entail improvements in diagnostic technologies, the emergence of new drug treatments, technological advancements in surgical apparatus, the provision of combination therapies, and the implementation of robotic surgery.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20820&type=smp
What External and Internal Drivers Are Contributing to the Growth of the Glaucoma Market?
The escalation in chronic eye-related illnesses is anticipated to skyrocket the growth of the glaucoma market. These are long-standing issues impacting the eye and often result in continuous visual impairment or discomfort, requiring unceasing observation or therapy. The increasing instances of such conditions are linked to aging demographics, prolonged screen exposure, lifestyle aspects, and the occurrence of conditions like diabetes and hypertension. Treating glaucoma is crucial for chronic ocular conditions to decrease intraocular pressure, avert further destruction of the optic nerve, and maintain sight, as glaucoma left unchecked can lead to unchangeable blindness. For example, figures from December 2024 released by the National Health Service (NHS), a healthcare system in the UK funded by the public, declared that over 2 million residents in the UK had sight loss in 2024. Additionally, the population with sight loss is expected to surge by 27%, reaching nearly 2.8 million by 2035. Consequently, the escalating occurrence of chronic ocular conditions is fuelling the glaucoma market.
What Segment Types Define the Glaucoma Market Structure?
The glaucoma market covered in this report is segmented –
1) By Disease Type: Open Angle Glaucoma, Angle Closure Glaucoma, Other Disease Types
2) By Diagnosis: Tonometry, Ophthalmoscopy, Perimetry, Gonioscopy
3) By Drug Class: Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Other Drug Classes
4) By Administration: Oral, Injections, Intravitreal, Other Administrations
5) By End-User: Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma
2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma, Secondary Angle Closure Glaucoma
3) By Other Disease Types: Normal-Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma, Congenital Glaucoma
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=20820&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Glaucoma Market?
North America was the largest region in the glaucoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glaucoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Current Market Growth and Trends in the Glaucoma Industry?
Leading firms in the glaucoma market are directing their focus towards the development of novel treatments, such as Rho-kinase (ROCK) inhibitors, which provide a dual course of action by reducing intraocular pressure through improved aqueous humor outflow and the relaxation of trabecular meshwork cells, making them a potent solution for glaucoma treatment. Rho-kinase (ROCK) inhibitors belong to a drug class that inhibits the function of Rho-kinase enzymes, pivotal in regulating cell contraction, and are utilized to manage glaucoma by reducing intraocular pressure. For example, in July 2023, Santen Pharmaceutical Co. Ltd., a Japanese firm known for eye care products, introduced Roclanda to the UK market. Roclanda, a fixed-dose combination (FDC) of latanoprost and netarsudil (a unique ROCK inhibitor), effectively manages intraocular pressure (IOP) by rectifying trabecular meshwork dysfunction and is prescribed for adults suffering from primary open-angle glaucoma or ocular hypertension inadequately controlled with singular prostaglandin or netarsudil treatment. With Roclanda’s launch in Europe, it’s the first of a new class of glaucoma medicine to hit the market in a quarter of a century, indicating a significant advancement in treatment options. Roclanda combines netarsudil and latanoprost and works in unison to enhance the trabecular (conventional) and uveoscleral (unconventional) outflows, offering a comprehensive solution for elevated IOP management.
View the full report here:
https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report
What Is the Definition of the Glaucoma Market?
Glaucoma is a group of eye disorders that cause damage to the optic nerve, typically resulting from increased intraocular pressure (IOP). This damage can lead to progressive, irreversible vision loss if untreated, making glaucoma one of the leading causes of blindness worldwide. Glaucoma is a leading cause of blindness worldwide, and early detection through regular eye exams is critical to prevent vision loss.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20820
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
